Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2020

摘要: Remarkable advances have been achieved in the treatment of multiple myeloma (MM) last decade, which saw targeted immunotherapy, represented by anti-CD38 monoclonal antibodies, successfully incorporated across indications. However, is still considered curable only a small subset patients, and majority them eventually relapse. B-cell maturation antigen (BCMA) expressed exclusively mature B lymphocytes plasma cells, represents an ideal new target for presented bispecific antibody (bsAb) constructs, antibody-drug conjugates (ADCs) chimeric receptor T (CAR-T) cells. Each has proved its efficacy with potential deep long-lasting responses as single agent therapy heavily pretreated patients. As result, belantamab mafodotin was approved United States Food Drug Administration relapsed/refractory MM, first anti-BCMA agent. In present review, we focus on antibodies targeting BCMA - bsAbs ADCs. The data from preclinical studies well first-in-human clinical trials will be reviewed, together coverage their constructs mechanisms action. results laid groundwork ongoing or upcoming combinatory regimens, always cornerstone MM.